News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM Yael L. Maxwell April 02, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020